Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial  by Green, Richard M. et al.
417
CLINICAL RESEARCH STUDIES
Three-year results of a multicenter randomized
prospective clinical trial determined that collagen-
impregnated knitted polyester velour (HMDV;
Hemashield Microvel Double Velour, Meadox
Medicals, Oakland, NJ) and thin-walled expanded
polytetrafluoroethylene (Gore-tex; W.L. Gore,
Flagstaff, Ariz) performed equally well as a conduit
from the common femoral artery to the above-knee
popliteal artery.1 This interim report identified
patient age, tobacco use, and graft diameter as vari-
ables that affected graft survival. 
Patency survival and the variables affecting paten-
cy of above-knee femoropopliteal prosthetic bypass
grafts at 5 years are examined in this final report. This
randomized prospective trial provides information
that, if heeded, should improve selection and opera-
tive results in the broad category of patients eligible
for this procedure. In addition, this prospective series
provides a current standard with which newer, less
invasive procedures and conventional autologous
venous bypass grafts can be compared.
MATERIALS AND METHODS
Patients. The institutional review boards of
each of the eight participating institutions
approved the experimental protocol. The first
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patient was enrolled on Nov 12, 1991, and the last
patient was enrolled on Jan 31, 1996. Patients were
eligible for this trial when they had: (1) an angio-
graphically demonstrated superficial femoral artery
occlusion with reconstitution of a popliteal seg-
ment above the knee, and (2) not undergone any
earlier infrainguinal vascular procedures. Patients
who had undergone earlier aortofemoral,
iliofemoral, and femorofemoral bypass grafting
procedures were eligible. Adjunctive inflow proce-
dures were not allowed at the time of the
femoropopliteal bypass grafting procedure. Two
hundred forty patients undergoing primary above-
knee femoropopliteal bypass grafting procedures at
eight institutions (Hahnemannn University
Hospital [66], University of Rochester [58],
Norfolk General Hospital [37], Jewish General
Hospital and Royal Victoria Hospitals in Montreal,
Quebec [28], Montefiore Medical Center [16],
Massachusetts General Hospital [16], Ocshner
Clinic [7], and Baptist Memorial Hospital in
Memphis [2]) were centrally randomized to receive
either Gore-tex or HMDV grafts by the operating
surgeon, after informed consent was obtained. Men
comprised 60.2% of the HMDV and 60.7% of the
Gore-tex groups. The women were older than the
men, 69.3 versus 65.7 years (SE, 0.3; P = .002).
Graft diameter and the type of postoperative anti-
coagulation, if any, was determined by the operat-
ing surgeon. No attempt was made to monitor
patient compliance with any anticoagulation regi-
men. Data pertaining to patient risk factors (dia-
betes mellitus, smoking, hypertension, and hyper-
lipidemia) and vascular risk factors (level of
ischemia, runoff status, preoperative ankle-brachial
index) were prospectively collected by study coor-
dinators and centrally entered into a database
designed and managed by Boston Scientific
Vascular for this study.
Patients were observed at 1, 3, 6, 12, 18, and 24
months after operation and then at yearly intervals
with clinical examination and ankle-brachial pressure
ratios. The original protocol allowed for additional
noninvasive investigations at the discretion of the
surgeon, but the protocol was amended in 1994 to
require both ankle-brachial pressure measurements
and duplex scans of the grafts at each follow-up visit.
This change was based on preliminary data that sug-
gested a predictive value for the duplex scan before
patency failure. The management of graft occlusion
was left to the discretion of each investigator.
Local study coordinators forwarded reports to
Boston Scientific Vascular, and site visits were made
regularly to monitor compliance. The database was
reconfigured post hoc to conform to the revised rec-
ommended standards for reports dealing with lower-
extremity ischemia.2
Statistical analysis. Calculations were done dur-
ing the study design period to provide for sufficient
numbers of patients to detect a difference in the two
graft materials, with a power of at least 0.80 and an
alpha of 0.05. The group comparison is the
strongest inference, because this is determined
prospectively by the study protocol. All other analy-
ses are post hoc, for the purpose of investigating fac-
tors possibly influencing patency survival. 
Univariate comparisons of patency between levels
of each prognostic variable were made with the
Kaplan-Meier estimate.3 Variables that had a univari-
ate P value less than .25 or those known to be impor-
tant but failing to meet the critical alpha level were
submitted to a Cox regression analysis to determine
the independent, multivariable predictors of patency.
All first order interactions were tested in this model.
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Interval at beginning of deaths
during interval
during Interval Cumulative
(mo) of interval during interval Time LTF interval survival rate survival rate (%) SE (%)
0 to 1 240 4 3 4 7 0.983 98.31 0.83
1 to 3 229 2 5 5 10 0.991 97.43 1.03
3 to 6 217 8 15 10 25 0.961 93.62 1.61
6 to 12 184 4 21 18 39 0.976 91.34 1.98
12 to 18 141 9 15 5 20 0.931 85.07 2.77
18 to 24 112 1 21 3 24 0.990 84.22 3.16
24 to 36 87 9 24 3 27 0.878 73.90 4.05
36 to 48 51 5 16 0 16 0.884 65.31 5.39
48 to 60 30 2 16 0 16 0.909 59.37 6.91
LTF, Lost to follow-up.
RESULTS
Patient and graft survival
Forty-four patients died during the study period.
The 5-year patient survival rate in this series was
59.4% (Table I). Associated cardiovascular disease
was responsible for 26 deaths, six patients died of
cancer, four patients died of miscellaneous causes,
and eight patients died of undetermined causes.
There were four deaths within 30 days of operation.
Two patients died of cardiac arrest (days 7 and 16),
another patient died of a pulmonary embolus (day
9), and one patient died after a stroke (day 13).
The mean follow-up period was 638 days ± 24.24
SE. The 5-year cumulative primary patency rate was
44% (Table II). The secondary patency rate at this
same interval was significantly higher, 67.3% (P = .5).
Seventy patients had at least one graft occlusion. The
occlusion was treated immediately in 29 patients by
means of either thrombolysis (22) or thrombectomy
(7) when urgent revascularization was required. The
degree of ischemia at the time of graft occlusion did
not correlate with the original indication for opera-
tion. Some patients originally undergoing surgery for
claudication had rest pain when their grafts occluded.
Thrombolysis alone was successful in 10 patients,
whose grafts remained patent for the remainder of
the study. Thrombolysis was unsuccessful or lesions
were identified that required placement of a new
bypass graft in 11 patients. One patient required a
below-the-knee amputation after unsuccessful
thrombolysis. Of the seven patients who underwent
immediate thrombectomy, the grafts remained
patent in four patients, one patient required a new
bypass graft, and two patients were left untreated
after rethrombosis occurred. Data were available in
26 patients after either successful thrombolysis or
operative revision, leaving us unable to comment on
the cause of failure (Table III). Popliteal artery
lesions, either representing anastomotic stenoses or
progression of occlusive disease, were thought to be
the cause of failure in 13 of the 26 patients. No
anatomic cause was identified in 12 of the 26 grafts
successfully treated.
Forty-one other patients had initial graft occlu-
sion that was not associated with limb-threatening
ischemia, and treatment was deferred. New bypass
grafts were subsequently required in 20 of these
patients for disabling claudication or rest pain. The
remaining 21 patients chose to live with their symp-
toms rather than undergo another procedure.
There were 10 amputations (4%) in this series,
five in each graft grouping. Six of the 10 amputa-
tions occurred within the first month, and all ampu-
tations occurred within the first year. In eight of the
10 patients, threatened tissue loss was the indication
for surgery. One patient requiring an amputation
entered the trial as a claudicator. In this patient, ran-
domized to HMDV, a hypercoagulable state devel-
oped because of advanced cancer. One other patient
entered the study with ischemic rest pain. 
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Table II. Primary patency data, entire series
No. at No. failed
Withdrawn
Interval Cumulative
Interval risk at start during
during interval
Total patency patency
(mo) of interval interval Time LTF Death withdrawn rate rate (%) SE (%)
0 to 1 240 4 3 4 4 11 0.983 98.29 0.83
1 to 3 225 5 4 4 2 10 0.977 96.06 1.27
3 to 6 210 14 6 9 8 23 0.929 89.29 2.02
6 to 12 173 19 9 11 3 23 0.882 78.78 2.76
12 to 18 131 9 10 4 8 22 0.925 72.87 3.32
18 to 24 100 8 15 2 0 17 0.913 66.50 3.85
24 to 36 75 2 18 1 8 27 0.967 64.34 4.44
36 to 48 46 5 12 0 5 17 0.867 55.76 5.47
48 to 60 24 4 8 0 2 10 0.789 44.02 6.72
Totals 70 85 35 40 160
LTF, Lost to follow=up.
Table III. Documented causes of graft failure 
Thrombolysis group Operative group





Iliac artery stenosis 1 0
Popliteal artery stenosis 4 1
None identified 8 4
Hemashield Microvel Double Velour Versus
Gore-tex
The patient and vascular risk factors are evenly
distributed between the two graft populations, with
the exception of diabetes mellitus, which was more
common in the Gore-tex group (P = .04), and
hypertension, which was more common in the
HMDV group (P = .0195; Tables IV and V). The 5-
year cumulative patency rates (Tables VI and VII)
were 45.3% for HMDV and 42.6% for Gore-tex (P
= NS). Similarly, no difference was noted in sec-
ondary patency rates at 5 years (68.4% vs 67.6%).
The incidences of wound complications (ie, graft
infection [2.7% vs 1.7%], wound infection [6.3% vs
10.1%], and seromas [4.5% vs 2.5%]) were similar
for HMDV and Gore-tex. Also, the incidences of
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Table IV. Patient risk factors
HMDV Gore-tex Total
N % N % N %
Diabetes mellitus
None 69 59.0 53 43.4 122 51.0
Adult, diet 19 16.2 30 24.6 49 20.5
Adult, insulin 27 23.1 33 27.0 60 25.1
Juvenile 2 1.7 6 4.9 8 3.3
Tobacco use
None 48 41.0 45 36.9 93 38.9
None, but smoked in the past 10 years 33 28.2 33 27.0 66 27.6
Current, < 1 pack per day 22 18.8 30 24.6 52 21.8
Current, > 1 pack per day 14 12.0 14 11.5 28 11.7
Hypertension
None 31 26.5 48 39.3 79 33.1
Easily controlled with single drug 41 35.0 40 32.8 81 33.9
Controlled with 2 drugs 30 25.6 25 20.5 55 23
Requires > 2 drugs 15 12.8 9 7.4 24 10.0
Lipid level
Normal 74 63.2 69 56.6 143 59.8
Mild, diet controlled 28 23.9 41 33.6 69 28.9
Type II, III, or IV, strict diet 5 4.3 3 2.5 8 3.3
Requires diet and drugs 10 8.5 9 7.4 19 7.9
HMDV, Collagen-impregnated knitted polyester velour grafts; Gore-tex, thin-walled expanded polytetrafluoroethylene grafts.
Table V. Level of ischemia and angiographic status
HMDV Gore-tex Total
N % N % N %
Level of ischemia*
Acute, viable 3 4.2 1 0.8 4 1.7
Acute, threatened 2 1.7 2 1.6 4 1.7
Reversible 0 0.0 0 0.0 0 0.0
Chronic, mild claudication 2 1.7 1 0.8 3 1.3
Chronic, moderate claudication 26 22.0 38 31.1 64 26.7
Chronic, severe claudication 40 33.9 35 28.7 75 31.1
Chronic, ischemic rest pain 17 14.4 9 7.4 26 10.8
Chronic, minor tissue loss 28 23.7 32 26.2 60 25.0
Chronic, major tissue loss 0 0.0 4 3.3 4 1.7
Outflow status*
3 vessels 29 25.0 33 27.3 62 26.2
2 vessels 45 38.8 47 38.8 92 38.8
1 vessel 31 26.7 36 29.8 67 28.3
Blind popliteal 11 9.5 5 4.1 16 6.8
Preoperative ankle-brachial index* 0.5 0.52 0.51
*P values not significant between Gore-tex and HMDV groups.
HMDV, Collagen-impregnated knitted polyester velour grafts; LTF, lost to follow-up.
myocardial infarction and/or congestive heart fail-
ure (8.1% vs 7.5%), stroke (3.6% vs 0.8%), and deep
venous thrombosis (3.6% vs 1.7%) were similar.
Risk factors for patency failure
Variables that did not affect patency survival
were smoking, hyperlipidemia, runoff, diabetes mel-
litus, hypertension, level of limb ischemia, and the
type of graft implanted.
Age
Patients were arbitrarily divided into a young
group, the members of which were younger than 65
years (N = 139), and an old group, the members of
which were 65 years or older (N = 101). The 5-year
patency rate of the old group exceeded that of the
young group, 55.2% versus 36.2% (P = .0491). The
5-year patency rate of grafts in young men was sig-
nificantly less than the rate in old men, 42.2% vs
70.2%, whereas no difference in patency was detect-
ed in the female population stratified by age, 26.7%
versus 26.7%. Age was a significant variable, whether
used as a categorical (younger than 65 years, P =
.0010) or a continuous (years, P = .0128) value.
Graft diameter. Graft diameters were classified
as small (5 or 6 mm) or large (7 or 8 mm). Either 5-
or 6-mm grafts were used in 71.6% of the series.
Although there was a tendency to use small grafts
more often in female patients, this was not a statisti-
cally significant finding. Small graft size was an
important variable affecting patency (P = .0143),
but its effect was sex dependent. The 5-year cumu-
lative patency rates for men with small and large
grafts were 37.9% and 69.1%, respectively (P =
.031). Similar comparisons in women show that the
5-year cumulative patency rates were 45% for both
large and small grafts. The Kaplan-Meier data for
cumulative graft patency for large and small diame-
ter grafts are shown in Fig 1.
Runoff. “Good” run-off was defined as having
the popliteal artery and two or three tibial vessels
patent to the foot. “Poor” runoff existed when either
one tibial vessel was patent to the foot or the popliteal
artery ended blindly. The 5-year cumulative patency
rate for grafts with good runoff was 34.9% and was
lower than the cumulative patency rate of 65.8% for
grafts with poor runoff, but this difference did not
reach statistical significance.
Smoking. Smoking was not a univariate predictor
of graft patency (P = .26). Any apparent effect is a
reflection of the higher incidence of smoking in the
population younger than 65 years. Patency at 1200
days for cohorts was the following (predicted proba-
bility ± SE): Age younger than 65 years, non-smoker,
51% ± 12%; Age older than 65 years, non-smoker, 68%
± 6%; Age younger than 65 years, smoker, 44% ± 10%;
Age older than 65 years, smoker 68% ± 10%; P = .013.
Smoking, by itself, without any other variable, did not
remain significant in a Cox model of patency.
Noninvasive laboratory testing. Ankle-brachial
indices and velocity data from duplex scans were ana-
lyzed to identify abnormalities that might predict
graft thrombosis. These data were compared with
velocities associated with failing autogenous venous
bypass grafts. Peak systolic velocity, either as a maxi-
mum or minimum number or a ratio between the
two, or decreases in the ankle-to-brachial pressure
index had no correlation with subsequent graft
thrombosis. Because the duplex scans were an adden-
dum to the protocol, sufficient data were not available
to make any statistical conclusions, because most graft
thromboses occurred before the protocol change.
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Fig 1. The Kaplan-Meier data for cumulative graft patency for large and small diameter grafts.
Cox proportional hazards model
The Cox model analysis is a method that pro-
vides likely hypotheses that must be confirmed by
means of a study prospectively designed to address
these issues. Two hundred thirty-six patients who
had all covariates were analyzed after stratification by
age as both a categorical (younger than 65 years,
older than 65 years) and continuous variable. The
hazard ratios are listed in Table VIII. The negative
effect of an age younger than 65 years and graft
diameter smaller than 7 mm reached statistical sig-
nificance (P < .05); adverse trends were noted in
patients with normal blood lipid levels (P = .07) and
two or three vessels with runoff (P = .08).
DISCUSSION
The original intent of this trial was to random-
ize the two different graft materials. These 5-year
results prove that HMDV and Gore-tex grafts do
not have different patency rates or, at least, that
there is no visible difference above the error of the
study. The patency rate of 44% after 5 years is at the
lower end of the range reported by other authors
for prosthetic grafts to the above-knee popliteal
artery4-6 and considerably lower than the series
reported by El-Massry et al.7 It is hard to compare
these series with the current series, because the
other series were retrospective analyses of data, and
results are often expressed on the basis of operative
indication. Our results suggest that if followed for
even longer periods, prosthetic bypass grafts would
continue to occlude at a rate exceeding that of
autogenous venous bypass grafts, which have 5-
and 10-year cumulative patency rates of 77%8 and
50%,9 respectively. Although this study was not
designed to compare prosthetic bypass grafts with
autogenous venous bypass grafts or evaluate the
concept of preferential use of a prosthetic to save
the vein, one cannot escape the disappointing 5-
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Table VI. Primary patency data, HMDV
No. at No. failed
Withdrawn
Interval Cumulative
Interval risk at start during
during interval
Total patency patency
(mo) of interval interval Time LTF Death withdrawn rate rate (%) SE (%)
0 to 1 118 0 2 1 3 6 1.000 100.00 0.00
1 to 3 112 2 2 2 2 6 0.982 98.17 1.26
3 to 6 104 7 4 5 2 11 0.929 91.19 2.65
6 to 12 86 12 5 3 1 9 0.853 77.76 3.95
12 to 18 65 6 5 1 4 10 0.900 69.99 4.76
18 to 24 49 3 9 1 0 10 0.932 65.21 5.49
24 to 36 36 0 7 0 4 11 1.00 65.21 6.41
36 to 48 25 3 5 0 3 8 0.857 55.90 7.42
48 to 60 14 2 5 0 2 7 0.810 45.25 8.9
Totals 35 49 13 21 83
HMDV, Collagen-impregnated knitted polyester velour grafts; LTF, lost to follow-up
Table VII. Primary patency, Gore-tex data
No. at No. failed
Withdrawn
Interval Cumulative
Interval risk at start during
during interval
Total patency patency
(mo) of interval interval Time LTF Death withdrawn rate rate (%) SE (%)
0 to 1 122 4 1 3 1 5 0.967 96.65 1.60
1 to 3 113 3 2 2 0 4 0.973 94.04 2.16
3 to 6 106 7 2 4 6 12 0.930 87.46 3.01
6 to 12 87 7 4 8 2 14 0.913 79.81 3.84
12 to 18 66 3 5 3 4 12 0.950 75.81 4.59
18 to 24 51 5 6 1 0 7 0.895 67.83 5.39
24 to 36 39 2 11 1 4 16 0.935 63.46 6.14
36 to 48 21 2 7 0 2 9 0.879 55.77 8.09
48 to 60 10 2 3 0 0 3 0.765 42.64 10.21
Totals 35 41 22 19 82
Gore-tex, Thin-walled expanded polytetrafluoroethylene grafts; LTF, lost to follow-up.
year results with prosthetic materials. Wilson et al
make an effective argument against preferential use
of prosthetic grafts.10 They examined their series of
112 above-knee femoropopliteal bypass grafts and
concluded that the 3-year results were superior for
autogenous vein, that the amputation rate after
graft failure was significantly higher when Gore-tex
was used, and that the secondary vein was only
rarely needed after Gore-tex failure.
The strong evidence that small-diameter grafts
have a greater risk of occlusion is counterintuitive.
One would expect that smaller-diameter grafts
would have higher flow velocities and fewer failures.
Our data do not support this hypothesis. First, there
are no data that demonstrate increased flow veloci-
ties in 5- and 6-mm grafts, as compared with 7- and
8-mm grafts. Second, our data do not support the
hypothesis that graft patency is in any way related to
the flow velocities found in these prosthetic grafts.
Most of our failures that had objective data regard-
ing the cause of failure were caused by a distal anas-
tomotic problem. The improved patency survival
rate for larger diameter grafts is most likely a result
of the larger anastomosis lessening the significance
of neointimal fibrous hyperplasia. These data strong-
ly support the use of a graft with a diameter of larg-
er than 7 mm whenever possible.
An apparent adverse sex influence on patency
survival in women was probably related to the use of
smaller grafts. Other studies have also shown that
the results of infrainguinal reconstruction in women
were comparable with those in men. Harris et al
found in a series of 823 infrainguinal arterial recon-
structions that mortality, patency, and salvage rates
were not statistically different between men and
women.11 Magnant et al found that results were
superior in women.
The improved graft patency rates in our patients
with poor runoff lends further support to the con-
cept that prosthetic bypass graft patency is not
dependent on flow velocities. Contradictory evi-
dence exists about the role of runoff on graft paten-
cy. Kram et al evaluated 217 bypass grafts to isolat-
ed popliteal segments.12 They found that the paten-
cy rates at 5 years were 59% for saphenous vein and
74% for Gore-tex (P < .05). In contrast, El-Massry
et al found that the single variable with a significant
adverse impact on patency rates of Dacron grafts was
poor outflow. No explanation for the variable effect
of poor runoff is forthcoming. Nonetheless, this
study does demonstrate that a prosthetic above-knee
femoropopliteal graft to an isolated popliteal seg-
ment is durable.
The original publication from this group found
that smoking had a significant negative impact on
graft patency.1 However, the smoking factor was
acknowledged to be confounded with the age factor,
because a higher proportion of smokers came from
the group of patients younger than 65 years; 85% of
the patients younger than 65 years indicated a smok-
ing history, compared with only 47% of the patients
older than 65 years. The association of smoking with
an increased tendency toward graft occlusion is most
likely an adverse effect of a young age on patency.
Prendiville et al also noted a decrease in Gore-tex
graft patency in patients who continue to smoke
after surgery.13 Cheshire et al measured plasma fi-
brinogen, lipoprotein (a), and serotonin in patients
with infrainguinal bypass grafts14 and found that
patients who smoked had a 61% incidence of graft
stenosis, compared with an incidence of only 21% in
those patients who did not smoke. Patients in whom
a stenosis developed had higher circulating levels of
fibrinogen, lipoprotein (a), and 5-hydroxytrypta-
mine. These data make a strong argument for keep-
ing these patients away from tobacco, but a study
directed at this issue will be required before a defin-
itive statement can be made.
These 5-year data can be used as a contemporary
standard to evaluate newer endovascular procedures
designed to treat superficial femoral artery occlu-
sions. Although none has produced results in any
way comparable with this series,15 newer covered
stents are at various stages of development and
structurally are not very different than a convention-
al above-knee femoropopliteal prosthetic graft. 
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Table VIII. Cox proportion hazards model con-
structed by using age as both a categorical and
continuous variable
Entering age as a categorical value:
Risk ratio 95% CI P value
Age < 65 years 2.103 1.30, 3.39 .0010
Graft diameter < 7 mm 1.635 0.91, 2.92 .0219
Hyperlipidemia 0.626 0.38, 1.04 .0694
Runoff (2 or 3 vessels) 1.603 1.0, 2.58 .0702
Entering age as a continuous variable:
Risk ratio 95% CI P value
Age (years) 0.974 0.95, 0.99 .0128
Graft diameter < 7 mm 1.753 0.99, 3.11 .0131
Hyperlipidemia 0.63 0.38, 1.05 .0727
Runoff (2 or 3 vessels) 1.561 0.97, 2.50 .0858
Failing prosthetic grafts were only identified in a
few instances, despite the frequency of graft surveil-
lance. No statistical conclusions could be reached
because of an inadequate sample size, however.
Although other authors have reported success with
prosthetic graft surveillance,16,17 these studies really
demonstrate that inflow and outflow disease pro-
gression that may threaten graft survival can be iden-
tified in some patients. Because graft lesions them-
selves are uncommon in patients with prosthetic
bypass grafts, graft surveillance programs akin to
those recommended for autogenous grafts are of
limited benefit.18
Finally, mention must be made of the 5-year
patient survival rate of only 59.4%. Our mortality data
are no different than those published in 1971 by
DeWeese and Rob, who looked at the 5-year results
of autogenous venous bypass grafting procedures,19
and Allen, Barker, and Hines, who examined patients
5 years after their initial visit to the Mayo Clinic for
lower-extremity occlusive disease in 1955.20 Deaths
in each of these series, spanning four decades, were
mostly caused by cardiac or cerebrovascular illnesses.
Perhaps the use of more aggressive screening for and
treatment of ischemic heart disease and stroke has not
significantly affected the malignant nature of the gen-
eralized atherosclerotic process. 
CONCLUSION
This series provides a unique data set from con-
temporary randomized and prospectively placed
prosthetic infrainguinal bypass grafts. It validates the
original hypothesis that the two graft materials,
Gore-tex and HMDV, behave in a similar fashion in
a reasonable follow-up period. Perhaps more impor-
tant, it reveals the adverse relationship between age
younger than 65 years and graft thrombosis and the
importance of selecting a large-diameter graft, how-
ever counterintuitive that choice may seem. Young
patients should not have prosthetic bypass grafting
for ischemia that does not cause rest pain or threat-
en tissue loss when the saphenous vein is unavailable,
unless the 5-year patency survival rate for prosthetic
materials of less than 50% is acceptable. 
We thank Michael Miller, PhD, and Joan Ivanov, RN,
MSc, for their assistance in study design, data analysis, and
interpretation and Susan Daum of Boston Scientific
Vascular for serving as project coordinator.
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